Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1813825

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1813825

U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report By Product (Sex Hormones, Thyroid Hormones), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 3950
Printable PDF & Excel (5-User License)
USD 4950
Printable PDF & Excel (Enterprise License)
USD 6950

Add to Cart

Market Size & Trends:

The U.S. hormone therapy (retail side) market size was estimated at USD 11.63 billion in 2024 and is projected to reach USD 19.22 billion by 2033, growing at a CAGR of 5.83% from 2025 to 2033. This growth is driven by an increasing aging population and rising hormonal disorder prevalence. In addition, advances in delivery technologies, including oral pills, transdermal patches, subcutaneous pellets, and injectables, have enhanced efficacy, convenience, and adherence.

Moreover, the pharmacies now offer convenient dispensing and counseling, and platforms such as Ro, Noom, and Midi Health bundle telemedicine, online prescribing, and at-home delivery of hormones, with some combining GLP-1 weight-loss treatments, driving sales upward.

U.S. Hormone Therapy (Retail Side) Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hormone therapy (retail side) market report based on product, indication, route of administration, and distribution channel:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Sex Hormones
    • Estrogen Replacement Therapy (ERT)
    • Testosterone Replacement Therapy (TRT)
    • Progesterone Therapy
    • Combined Hormone Therapy
  • Thyroid Hormones
  • Growth Hormones
  • Adrenal Hormones
  • Other Hormones
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Menopause & Andropause Management
  • Hypothyroidism
  • Hypogonadism
  • Growth Hormone Deficiency
  • Gender Affirming Therapy
  • Fertility Treatment
  • Cosmetic Applications
  • Other Indications
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Parenteral
  • Transdermal
  • Other Route of Administration
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Offline Retail Pharmacies
    • Large chains
    • Independent pharmacies
  • Online Pharmacies / Telehealth
    • Pure-play online pharmacies
    • Telehealth & subscription-based DTC brands
  • Others (Specialized Hormone Clinics)
Product Code: GVR-4-68040-700-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Hormone Therapy (Retail Side) Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product & indication segment outlook
      • 2.1.2.2. Route of administration & distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrants
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis in Online vs. Offline Channels
  • 3.7. Consumer Awareness Trends for Hormone Therapy
  • 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Product Business Analysis

  • 4.1. U.S. Hormone Therapy (Retail Side) Market: Product Movement Analysis
  • 4.2. U.S. Hormone Therapy (Retail Side) Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Product
  • 4.5. Sex Hormones
    • 4.5.1. Sex Hormones Market, 2021 - 2033 (USD Million)
    • 4.5.2. Estrogen Replacement Therapy (ERT)
      • 4.5.2.1. Estrogen Replacement Therapy (ERT) market, 2021 - 2033 (USD Million)
    • 4.5.3. Testosterone Replacement Therapy (TRT)
      • 4.5.3.1. Testosterone Replacement Therapy (TRT) market, 2021 - 2033 (USD Million)
    • 4.5.4. Progesterone Therapy
      • 4.5.4.1. Progesterone therapy market, 2021 - 2033 (USD Million)
    • 4.5.5. Combined Hormone Therapy
      • 4.5.5.1. Combined hormone therapy market, 2021 - 2033 (USD Million)
  • 4.6. Thyroid Hormones
    • 4.6.1. Thyroid Hormones Market, 2021 - 2033 (USD Million)
  • 4.7. Growth Hormones
    • 4.7.1. Growth Hormones Market, 2021 - 2033 (USD Million)
  • 4.8. Adrenal Hormones
    • 4.8.1. Adrenal Hormones Market, 2021 - 2033 (USD Million)
  • 4.9. Other Hormones
    • 4.9.1. Other Hormones Market, 2021 - 2033 (USD Million)

Chapter 5. Indication Business Analysis

  • 5.1. U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis
  • 5.2. U.S. Hormone Therapy (Retail Side) Market: Indication Segment Dashboard
  • 5.3. Indication Movement & Market Share Analysis, 2024 & 2033
  • 5.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Indication
  • 5.5. Menopause & Andropause Management
    • 5.5.1. Menopause & Andropause Management Market, 2021 - 2033 (USD Million)
  • 5.6. Hypothyroidism
    • 5.6.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
  • 5.7. Hypogonadism
    • 5.7.1. Hypogonadism Market, 2021 - 2033 (USD Million)
  • 5.8. Growth Hormone Deficiency
    • 5.8.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
  • 5.9. Gender Affirming Therapy
    • 5.9.1. Gender Affirming Therapy Market, 2021 - 2033 (USD Million)
  • 5.10. Fertility Treatment
    • 5.10.1. Fertility Treatment Market, 2021 - 2033 (USD Million)
  • 5.11. Cosmetic Applications
    • 5.11.1. Cosmetic Applications Market, 2021 - 2033 (USD Million)
  • 5.12. Other Indications
    • 5.12.1. Other Indications Market, 2021 - 2033 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis
  • 6.2. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Segment Dashboard
  • 6.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
  • 6.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Route of Administration
  • 6.5. Oral
    • 6.5.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.6. Parenteral
    • 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 6.7. Transdermal
    • 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)
  • 6.8. Other Route of Administration
    • 6.8.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis
  • 7.2. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Segment Dashboard
  • 7.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
  • 7.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Distribution Channel
  • 7.5. Offline Retail Pharmacies
    • 7.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
    • 7.5.2. Large Chains
      • 7.5.2.1. Large chains market, 2021 - 2033 (USD Million)
    • 7.5.3. Independent Pharmacies
      • 7.5.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies / Telehealth
    • 7.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
    • 7.6.2. Pure-Play Online Pharmacies
      • 7.6.2.1. Pure-play online pharmacies market, 2021 - 2033 (USD Million)
    • 7.6.3. Independent Pharmacies
      • 7.6.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.7. Telehealth & subscription-based DTC brands
    • 7.7.1. Telehealth & subscription-based DTC brands Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization (Offline Pharmacies)
  • 8.2. Company Categorization (Online Pharmacies)
  • 8.3. Company Categorization (Specialized Hormone Clinics)
  • 8.4. Participant's Overview
    • 8.4.1. Offline Pharmacies
    • 8.4.2. Online Pharmacies
    • 8.4.3. Specialized Hormone Clinics
  • 8.5. Company Market Position Analysis
  • 8.6. Strategy Mapping
    • 8.6.1. Regional Expansion
    • 8.6.2. Mergers & Acquisitions
    • 8.6.3. Others
  • 8.7. Company Profiles/Listing
  • 8.8. Offline Pharmacies
    • 8.8.1. CVS Health
      • 8.8.1.1. Overview
      • 8.8.1.2. Financial performance
      • 8.8.1.3. Product benchmarking
      • 8.8.1.4. Strategic initiatives
    • 8.8.2. Walgreens Boots Alliance, Inc.
      • 8.8.2.1. Overview
      • 8.8.2.2. Financial performance
      • 8.8.2.3. Product benchmarking
      • 8.8.2.4. Strategic initiatives
    • 8.8.3. Walmart Pharmacy
      • 8.8.3.1. Overview
      • 8.8.3.2. Financial performance
      • 8.8.3.3. Product benchmarking
      • 8.8.3.4. Strategic initiatives
    • 8.8.4. Rite Aid Corp
      • 8.8.4.1. Overview
      • 8.8.4.2. Financial performance
      • 8.8.4.3. Product benchmarking
      • 8.8.4.4. Strategic initiatives
    • 8.8.5. The Kroger Co.
      • 8.8.5.1. Overview
      • 8.8.5.2. Financial performance
      • 8.8.5.3. Product benchmarking
      • 8.8.5.4. Strategic initiatives
    • 8.8.6. Albertsons
      • 8.8.6.1. Overview
      • 8.8.6.2. Financial performance
      • 8.8.6.3. Product benchmarking
      • 8.8.6.4. Strategic initiatives
    • 8.8.7. Publix
      • 8.8.7.1. Overview
      • 8.8.7.2. Financial performance
      • 8.8.7.3. Product benchmarking
      • 8.8.7.4. Strategic initiatives
    • 8.8.8. Costco Wholesale Corporation
      • 8.8.8.1. Overview
      • 8.8.8.2. Financial performance
      • 8.8.8.3. Product benchmarking
      • 8.8.8.4. Strategic initiatives
    • 8.8.9. Meijer, Inc.
      • 8.8.9.1. Overview
      • 8.8.9.2. Financial performance
      • 8.8.9.3. Product benchmarking
      • 8.8.9.4. Strategic initiatives
  • 8.9. Online Pharmacies
  • 8.10. Hims & Hers Health, Inc
    • 8.10.1. CVS Health
      • 8.10.1.1. Overview
      • 8.10.1.2. Financial performance
      • 8.10.1.3. Product benchmarking
      • 8.10.1.4. Strategic initiatives
    • 8.10.2. Ro (Roman Health Ventures Inc.)
      • 8.10.2.1. Overview
      • 8.10.2.2. Financial performance
      • 8.10.2.3. Product benchmarking
      • 8.10.2.4. Strategic initiatives
    • 8.10.3. Lemonaid Health, Inc.
      • 8.10.3.1. Overview
      • 8.10.3.2. Financial performance
      • 8.10.3.3. Product benchmarking
      • 8.10.3.4. Strategic initiatives
    • 8.10.4. Mark Cuban Cost Plus Drug Company, PBC
      • 8.10.4.1. Overview
      • 8.10.4.2. Financial performance
      • 8.10.4.3. Product benchmarking
      • 8.10.4.4. Strategic initiatives
    • 8.10.5. Amazon.com, Inc.
      • 8.10.5.1. Overview
      • 8.10.5.2. Financial performance
      • 8.10.5.3. Product benchmarking
      • 8.10.5.4. Strategic initiatives
    • 8.10.6. Blink Health Administration LLC, Inc.
      • 8.10.6.1. Overview
      • 8.10.6.2. Financial performance
      • 8.10.6.3. Product benchmarking
      • 8.10.6.4. Strategic initiatives
    • 8.10.7. GoodRx, Inc
      • 8.10.7.1. Overview
      • 8.10.7.2. Financial performance
      • 8.10.7.3. Product benchmarking
      • 8.10.7.4. Strategic initiatives
    • 8.10.8. Honeybee Health Inc.
      • 8.10.8.1. Overview
      • 8.10.8.2. Financial performance
      • 8.10.8.3. Product benchmarking
      • 8.10.8.4. Strategic initiatives
    • 8.10.9. TruePill
      • 8.10.9.1. Overview
      • 8.10.9.2. Financial performance
      • 8.10.9.3. Product benchmarking
      • 8.10.9.4. Strategic initiatives
    • 8.10.10. NURX Inc.
      • 8.10.10.1. Overview
      • 8.10.10.2. Financial performance
      • 8.10.10.3. Product benchmarking
      • 8.10.10.4. Strategic initiatives
    • 8.10.11. AgelessRx
      • 8.10.11.1. Overview
      • 8.10.11.2. Financial performance
      • 8.10.11.3. Product benchmarking
      • 8.10.11.4. Strategic initiatives
  • 8.11. Specialized Hormone Clinics
  • 8.12. Hims & Hers Health, Inc
    • 8.12.1. BodyLogicMD
      • 8.12.1.1. Overview
      • 8.12.1.2. Financial performance
      • 8.12.1.3. Product benchmarking
      • 8.12.1.4. Strategic initiatives
    • 8.12.2. Defy Medical
      • 8.12.2.1. Overview
      • 8.12.2.2. Financial performance
      • 8.12.2.3. Product benchmarking
      • 8.12.2.4. Strategic initiatives
    • 8.12.3. Renew Vitality
      • 8.12.3.1. Overview
      • 8.12.3.2. Financial performance
      • 8.12.3.3. Product benchmarking
      • 8.12.3.4. Strategic initiatives
    • 8.12.4. Victory Men's Health
      • 8.12.4.1. Overview
      • 8.12.4.2. Financial performance
      • 8.12.4.3. Product benchmarking
      • 8.12.4.4. Strategic initiatives
    • 8.12.5. Hone Health
      • 8.12.5.1. Overview
      • 8.12.5.2. Financial performance
      • 8.12.5.3. Product benchmarking
      • 8.12.5.4. Strategic initiatives
    • 8.12.6. Joi & Blokes
      • 8.12.6.1. Overview
      • 8.12.6.2. Financial performance
      • 8.12.6.3. Product benchmarking
      • 8.12.6.4. Strategic initiatives
    • 8.12.7. Ways2Well
      • 8.12.7.1. Overview
      • 8.12.7.2. Financial performance
      • 8.12.7.3. Product benchmarking
      • 8.12.7.4. Strategic initiatives
    • 8.12.8. Honeybee Health Inc.
      • 8.12.8.1. Overview
      • 8.12.8.2. Financial performance
      • 8.12.8.3. Product benchmarking
      • 8.12.8.4. Strategic initiatives
    • 8.12.9. 4Ever Young Anti-aging Solutions
      • 8.12.9.1. Overview
      • 8.12.9.2. Financial performance
      • 8.12.9.3. Product benchmarking
      • 8.12.9.4. Strategic initiatives
    • 8.12.10. T CLINICS USA
      • 8.12.10.1. Overview
      • 8.12.10.2. Financial performance
      • 8.12.10.3. Product benchmarking
      • 8.12.10.4. Strategic initiatives
Product Code: GVR-4-68040-700-4

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. hormone therapy (Retail Side) market, by product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Hormone Therapy (Retail Side) Market: Strategy Mapping by Product
  • Table 5 U.S. hormone therapy (Retail Side) market, by indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Hormone Therapy (Retail Side) Market: Product and Strategy Mapping by Indication
  • Table 7 U.S. hormone therapy (Retail Side) market, by route of administration, 2021 - 2033 (USD Million)
  • Table 8 U.S. Hormone Therapy (Retail Side) Market: Route of Administration and Strategy Mapping by Route of Administration
  • Table 9 U.S. hormone therapy (Retail Side) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 10 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel and Strategy Mapping by Route of Administration

List of Figures

  • Fig. 1 U.S. hormone therapy (Retail Side) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook
  • Fig. 10 Segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. hormone therapy (Retail Side) market lineage outlook
  • Fig. 13 U.S. hormone therapy (Retail Side) market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. hormone therapy (Retail Side) market: PESTLE analysis
  • Fig. 17 U.S. hormone therapy (Retail Side) market: Porter's five forces analysis
  • Fig. 18 U.S. hormone therapy (Retail Side) market: Product segment dashboard
  • Fig. 19 U.S. hormone therapy (Retail Side) market: Product market share analysis, 2024 & 2033
  • Fig. 20 Sex hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Estrogen Replacement Therapy (ERT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Testosterone Replacement Therapy (TRT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Progesterone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Combined hormone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Thyroid hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Growth hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Adrenal hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Other hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. hormone therapy (retail side) market: Indication outlook key takeaways
  • Fig. 30 U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis (USD Million)
  • Fig. 31 Menopause & andropause management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hypothyroidism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Hypogonadism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Growth hormone deficiency market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Gender affirming therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Fertility treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cosmetic applications market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. hormone therapy (retail side) market: Route of administration outlook key takeaways
  • Fig. 40 U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis (USD Million)
  • Fig. 41 Oral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Parenteral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Transdermal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. hormone therapy (retail side) market: Distribution channel outlook key takeaways
  • Fig. 46 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis (USD Million)
  • Fig. 47 Offline retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Large chains market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Independent pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Online pharmacies / telehealth market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Pure-play online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Telehealth & subscription-based DTC brands market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Others (specialized hormone clinics) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Competition categorization (Offline Pharmacies)
  • Fig. 55 Competition categorization (Online Pharmacies)
  • Fig. 56 Competition categorization (Specialized Hormone Clinics)
  • Fig. 57 Company market position analysis
  • Fig. 58 Company market position analysis
  • Fig. 59 Company market position analysis
  • Fig. 60 Strategy mapping
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!